Product Images Ajovy
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 32 images provide visual information about the product associated with Ajovy NDC 51759-204 by Teva Pharmaceuticals Usa, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - image 1
This is a graph showing the change in the number of monthly migraine days from baseline for four different treatments: placebo, AJOVY 675 mg quarterly, AJOVY 225 mg monthly, and an unspecified treatment denoted by "A & A." The graph displays the least-square means and standard error of the mean for baseline, month 1, month 2, and month 3.*
clock image - image 10
Figure E - image 11
Figure F - image 12
Figure G - image 13
Step 9 image - image 14
Figure H - image 15
The text is describing a set of instructions to hold something down for 10 seconds. It is unclear what specifically is being held down as no additional information is provided.*
Step 12 image - image 16
Carton Part 1 - image 17
Carton Part 2 - image 18
This appears to be a diagram or labeled image of a syringe with annotations for a needle cap, expiration date label, thumb pad, syringe body, and finger flange.*
image 19
Figure 2 - image 2
This is a graph showing the percentage of patients with varying levels of migraine days per month for three different treatments: placebo, AJOVY 675 mg quarterly, and AJOVY 225 mg monthly. The x-axis shows the range of migraine days per month from 0 to over 12. The y-axis shows the percentage of patients in each treatment group falling within the different migraine day ranges. The graph indicates that AJOVY 675 mg quarterly and AJOVY 225 mg monthly have a higher percentage of patients with fewer migraine days per month compared to the placebo group.*
image 20
image 21
image 22
This appears to be a list of medical supplies which includes gauze pads or cotton balls, a sharps container, alcohol swab, and a pre-filled syringe for a medication called AJOVY.*
image 23
image 24
image 25
image 26
Do not put the needle cap back on the prefilled syringe.*
image 27
image 28
image 29
Figure 3 - image 3
The text describes the change of monthly headache days of at least moderate severity for patients taking AJOVY 675mg quarterly or AJOVY 225mg monthly, presented in baseline and months 1-3. LS means and standard errors are included in the data. This information is useful for evaluating the effectiveness of these medications in reducing headache days.*
image 30
This appears to be a product label for AJOVY (remanezumab), which is likely a medication administered via injection.*
image 31
image 32
Figure 4 - image 4
This text seems to be a graph indicating the percentage of patients and the number of headache days of at least moderate severity per month for a placebo group and two different doses of a medication called AJOVY. The x-axis indicates the number of headache days while the y-axis indicates the percentage of patients. The AJOVY treatment groups (675 mg Quarterly and 225 mg Monthly) have lower percentages of patients experiencing more headache days compared to the placebo group. There is also a key indicating the dosage groups and a legend indicating the change in headache days.*
Figure A - image 5
Figure B - image 6
stop image - image 7
Figure C - image 8
Figure D - image 9
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.